PANTHEON 2020

Recognizing Progress in an Unprecedented Year

Thursday, December 3, 2020 | Virtual

California Life Sciences AssociationCalifornia Life Sciences Association

Deal of the Year

Arena Pharmaceuticals Logo
Arena Pharmaceuticals, Inc. is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally. Arena’s proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune-mediated and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn’s disease (CD), as well as in programs for other indications such as atopic dermatitis. Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure (DHF).

Arena has additional license agreements and partnerships, including with United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension), Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and United Therapeutics Corporation (Nasdaq: UTHR) completed a global license agreement for an Arena-discovered Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).

United Therapeutics is a world-class company with a long-standing, deep commitment to the PAH community. Upon closing on January 24, 2019, United Therapeutics paid a non-refundable upfront cash payment of $800 million to Arena. Arena is eligible to receive potential milestone payments totaling up to $400 million based on the achievement of certain regulatory events and low double-digit tiered royalties on annual net sales of ralinepag. Upon closing, United Therapeutics received exclusive, worldwide rights to ralinepag.

Read More about Arena Pharmaceuticals